Mechanisms of resistance to anti-EGFR therapy in colorectal cancer

Ben Zhao¹, Lu Wang¹, Hong Qiu¹, Mingsheng Zhang¹, Li Sun¹, Ping Peng¹, Qianqian Yu¹ and Xianglin Yuan¹

¹ Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China

Correspondence to: Xianglin Yuan, email: yxl@medmail.com.cn
Keywords: colorectal cancer, epidermal growth factor receptor, targeted drug, primary resistance, acquired resistance
Received: May 31, 2016  Accepted: December 05, 2016  Published: December 18, 2016

ABSTRACT

Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy is effective for patients with RAS wild type metastatic colorectal cancer (mCRC). However, only a small percentage of mCRC patients are sensitive to anti-EGFR therapy and even the best cases finally become refractory to this therapy. It has become apparent that the RAS mutations correlate with resistance to anti-EGFR therapy. However, these resistance mechanisms only account for nearly 35% to 50% of nonresponsive patients, suggesting that there might be additional mechanisms. In fact, several novel pathways leading to escape from anti-EGFR therapy have been reported in recent years. In this review, we provide an overview of known and novel mechanisms that contribute to both primary and acquired anti-EGFR therapy resistance, and enlist possible treatment strategies to overcome or reverse this resistance.

INTRODUCTION

Colorectal cancer (CRC) ranks among the third most common human malignant diseases and is one of the leading causes of cancer-related deaths globally [1, 2]. In recent years, new anticancer drugs that target oncogenic signaling pathways have been developed and have demonstrated a prominent efficacy in the treatment of metastatic colorectal cancer (mCRC). Two representative examples of such drugs are cetuximab and panitumumab, two monoclonal antibodies (moAbs) against the epidermal growth factor receptor (EGFR), which have been proven to be effective for patients with RAS wild type (RAS-WT) mCRC in randomized clinical trials [3-9]. However, only a small percentage of mCRC patients are sensitive to anti-EGFR therapy [10], and even those who initially respond to the therapy eventually develop resistance to it [11-13]. Numerous studies have been conducted to explore resistance mechanisms to EGFR blockade, and it seems that several biomarkers and pathways are involved in the development of resistance to anti-EGFR therapy. Here, we provide an overview of these potential resistance mechanisms that can facilitate further improvement of anti-EGFR therapies.

EGFR (also called ERBB1/HER1) is a transmembrane receptor tyrosine kinase (RTK) belonging to the ERBB-family. Cetuximab and panitumumab bind to the extracellular domain of EGFR, thereby preventing activation of the receptor tyrosine kinase and of multiple downstream signal transduction cascades that are related to cell survival, proliferation, metastasis, and angiogenesis (Figure 1) [14, 15]. Among the major downstream pathways activated by EGFR, the RAS-RAF-MAPK, PI3K-PTEN-AKT, and JAK/STAT pathways have also been implicated in the resistance mechanisms against antibody-mediated EGFR inhibition [16]. Any alterations in their components, such as KRAS, NRAS, BRAF, and PIK3CA gene mutations, can lead to constitutive activation of EGFR and the ensuing intracellular signaling and ultimately, to drug resistance [17, 18]. In the following sections, we discuss recent research concerning anti-EGFR therapy and present an overview of the possible mechanisms that may contribute to the development of primary and secondary resistance to anti-EGFR therapy in mCRC.

PRIMARY RESISTANCE TO ANTI-EGFR THERAPY IN CRC

Early studies have demonstrated that about 80% of unselected mCRCs do not benefit from anti-EGFR therapy [2, 19-21], suggesting that primary resistance to anti-
EGFR therapy is common in CRC. Consequently, new drugs that target a single EGFR still have great limitations in the treatment of mCRC.

**Alterations in EGFR and EGFR ligands**

Alterations of the EGFR, including EGFR gene copy number and EGFR-specific ligands, have been considered in recent years, and both have been confirmed to be associated with responses to EGFR inhibitors in retrospective clinical trials [22, 23].

**Low EGFR gene copy number**

It is certain that preclinical and/or clinical studies with an EGFR-targeted agent often demonstrated the complex relationship between EGFR alterations (somatic mutations and gene copy number variations) and the efficacy of the anti-EGFR therapy. In 2004, Thomas et al. found that mutations in EGFR strikingly correlate with the clinical responsiveness to EGFR tyrosine kinase inhibitors (TKI) in patients with non-small-cell lung cancer (NSCLC) [24]. A similar result was observed in the use of the anti-HER2/neu receptor moAb trastuzumab for patients with metastatic breast cancer, in which the degree of HER2 expression correlates with response to trastuzumab [25]. However, mutations in the EGFR kinase domain are an extremely rare event in patients with CRC, and when they do occur, they are not associated with patient response [26]. Therefore, numerous studies were focused on the altered gene copy number of EGFR [22, 27, 28].

In a cohort study examining the correlation between EGFR gene copy number and clinical response to anti-EGFR therapy [22], about 90% of patients with objective responses after cetuximab or panitumumab treatment showed increased EGFR copy number (assessed by fluorescence in situ hybridization, FISH). In contrast, only 5% of the non-responders showed an increased EGFR copy number. More importantly, these data...
indicate that almost none of the patients (20 of 21 non-responders) with a low \(\text{EGFR}\) gene copy number could benefit from anti-\(\text{EGFR}\) therapy. Subsequently, Sartore-Bianchi et al. obtained a similar result in a larger and more homogeneous cohort [27]. Both analyses indicate that \(\text{EGFR}\) gene copy number might contribute to resistance to anti-\(\text{EGFR}\) therapy. Nevertheless, the degree of \(\text{EGFR}\) expression does not seem to correlate with effectiveness of \(\text{EGFR}\) inhibitors, therefore, the mechanism thereby the \(\text{EGFR}\) copy number influences the response to \(\text{EGFR}\)-targeted drugs remains unknown and requires more exploration. Moreover, due to technical obstacles and considerable discrepancies between scoring systems at present, evaluation of sensitivity to anti-\(\text{EGFR}\) drugs through estimation of \(\text{EGFR}\) gene copy number is still unpractical in clinical practice [29, 30].

Low expression of AREG and EREG

AREG and EREG are \(\text{EGFR}\)-specific ligands that have a key effect on intracellular signaling and are strongly related with response to anti-\(\text{EGFR}\) therapy. For example, in a prospective clinical trial of 110 patients with mCRC [23], the \(\text{AREG}\) and \(\text{EREG}\) gene expression levels, which were measured from pre-treatment metastatic biopsies, were found to be associated with cetuximab efficacy. Data from gene expression profiles show that patients with tumors expressing high levels of the \(\text{EGFR}\) ligands AREG and EREG, are more likely to respond to cetuximab (AREG, \(P = 0.000015\); EREG, \(P = 0.000025\)) when compared with patients showing low expression of these ligands. A later study on larger cohorts described a similar observation in \(\text{KRAS}\) wild type (WT) patients [31]. In this study, the gene expression of both EREG and AREG, as well as the status of \(\text{KRAS}\) were taken into account. In patients with \(\text{KRAS}\) WT tumors, there was a significant

![Aberrated genetic alterations in the members of EGFR signaling pathways induce resistance to anti-EGFR therapy](image)

**Figure 2: Aberrated genetic alterations in the members of EGFR signaling pathways induce resistance to anti-EGFR therapy.** Aberrated genetic alterations, including RAS, BRAF, PIK3CA, EGFR S492R mutations, PTEN loss, and STAT3 phosphorylation contribute to the resistance through constitutive activation of EGFR downstream signaling cascades regardless of EGFR blockade. The molecules implicated in EGFR signaling and affected by resistant alterations are highlighted in special colors and described in note.
correlation between EREG and AREG expression levels and progression-free survival (PFS) and overall survival (OS). For example, in the high EREG expression group, the median OS was 65 weeks, whereas in the low EREG expression group, it was 31 weeks. Similar data were obtained for AREG. Interestingly, KRAS WT patients with low ligand expression essentially respond like those with KRAS mutant tumors, and both show the worst response to cetuximab. In summary, low AREG and EREG gene expression levels correlate with resistance to anti-EGFR therapy. In fact, the expression of AREG and EREG is coordinately regulated, and plays an important role in tumor growth and survival by generating an autocrine loop through EGFR (Figure 1). Low levels of expression of AREG and EREG may characterize a tumor that is less dependent on EGFR and, therefore, particularly prone to develop resistance to EGFR inhibitors.

All the data presented above identify a relationship between EGFR copy number and EGFR ligand expression, and outcome. Altogether, these findings clearly demonstrate that anti-EGFR mAbs are likely to work most efficiently against amplified targets.

**RAS mutation**

RAS family genes (including KRAS, NRAS and HRAS) that encode guanosine-5′-triphosphate (GTP)-binding proteins play important roles in EGFR-activated signaling pathways [21, 32]. Activating mutations in RAS are common in CRC. RAS mutations are detected in about 50% of CRC patients; KRAS mutations are found in about 40% of cases, NRAS mutations are found in about 3-5% of cases, and HRAS mutations are negligible events [33, 34]. Mutations in RAS genes often lead to constitutive activation of RAS proteins and RAS downstream effector pathways (Figure 2). Persistent downstream signaling through the RAS axis can activate multiple processes.

---

**Figure 3: Aberrated activations of the bypass pathways induce resistance to anti-EGFR therapy.** EGFR downstream effectors can be activated by alternative and/or compensatory membrane growth factors, including IGF-1R, MET, HER2, and VEGFR. These growth factors then trigger intracellular signaling pathways bypassing EGFR and induce tumor cell growth and proliferation, and lead resistance to anti-EGFR therapy.
involved in tumor progression and metastasis without the influence of EGFR and other cell surface receptor kinases [32]. Therefore, it can be readily anticipated that mutations in the RAS gene will play a major role in primary resistance to anti-EGFR therapy.

**KRAS exon 2 mutations**

In CRC, about 85-90% of KRAS mutations occur in exon 2 (codons 12 and 13) [21, 35]. A large number of retrospective trials over the last decade have strongly suggested that patients with KRAS mutations in codon 12 or 13 do not benefit from anti-EGFR therapy [3, 5, 36, 37]. Indeed, KRAS exon 2 mutations are by far the most common predictor of resistance to the anti-EGFR drugs cetuximab and panitumumab in patients with mCRC, and have been used to plan appropriately the treatment regimen in clinical practice. All CRC patients are now compulsively tested for seven mutations in the KRAS codons 12 and 13 before receiving cetuximab or panitumumab [20].

However, conflicting data exist regarding the codon 13 mutation (G13D) of KRAS gene [38, 39]. A large number of retrospective studies indicated that patients carrying the KRAS G13D mutation might derive benefit from treatment with cetuximab [38]. In this analysis, that data of 579 patients with chemotherapy-refractory CRC treated with cetuximab from seven studies were pooled together. Finally, patients with the KRAS G13D mutant tumors achieved better OS and PFS in comparison with patients with tumors harboring other KRAS mutations (OS: 7.6 VS 5.7mon, HR = 0.50, P = 0.004; PFS: 4.0 VS 1.9mon, HR = 0.51, P = 0.005). A positive correlation was found between KRAS G13D mutations and OS benefit with cetuximab treatment. Moreover, a further analysis that investigated the updated pooled data sets from the CRYSTAL and OPUS studies designed by Tejpar et al. also shows a similar result [39]. In contrast, a more recent retrospective analysis of 110 patients treated with cetuximab, indicates that patients with KRAS G13D mutations were unlikely to respond to cetuximab [40]. There was no significant difference between patients carrying KRAS G13D mutations and patients with other KRAS mutations in terms of OS and PFS (OS: 8.2 VS 14.6mon, HR = 0.50, P = 0.084; PFS: 4.96 VS 3.1mon, HR = 0.88, P = 0.72). Consistent with the above analysis, patients with tumors harboring the KRAS G13D mutations were unlikely to benefit from panitumumab therapy in a pooled analysis of three randomized phase III trials [41].

Overall, due to the limitations of the retrospective nature of the present analysis and the low number of patients with such specific mutations, the role of KRAS G13D mutations in the mechanism of primary resistance to anti-EGFR therapies remains controversial.

**Extended RAS: NRAS and other KRAS mutations**

Recently, it has been shown that the mutational status of other RAS family genes outside exon 2 is also associated with response to anti-EGFR therapy [42-45]. In an updated analysis of the randomized phase III CRYSTAL study, the treatment outcomes of patients with KRAS exon 2 wild-type tumors were reassessed with respect to additional RAS mutations (KRAS exons 3 and 4; NRAS exons 2, 3 and 4) [46]. In summary, Van Cutsem et al. found that approximately 15% (63/430 patients) of patients with the KRAS exon 2 wild type disease had other RAS mutations. The presence of these extended RAS mutations was associated with poor response to additional use of cetuximab for both PFS (7.2 VS 6.9mon, HR = 0.81, P = 0.56) and OS (18.2 VS 20.7mon, HR = 1.22, P = 0.50). In contrast, patients with tumors that had no RAS mutations showed significantly longer PFS (11.4 VS 8.4mon, HR = 0.56, P < 0.001) and OS (28.4 VS 20.2mon, HR = 0.69, P = 0.0024) when cetuximab was added to chemotherapy. Thus, similar to findings in patients with KRAS exon 2 mutations, additional RAS mutations might also play an important role in anti-EGFR therapy resistance in patients with mCRC.

Furthermore, a recent subset analysis of data from the PRIME trial showed a consistent result that mutations occurring beyond the KRAS exon 2 could predict a lack of clinical benefit from Panitumumab administered in combination with first-line chemotherapy [44]. In this study, Doulliard et al. present the negative effects of panitumumab treatment with FOLOFX4 on PFS and OS in patients with tumors bearing mutations in KRAS exon 3 (at codon 61) or 4 (at codons 117 and 146), or in NRAS exon 2 (at codons 12 and 13), 3 (at codon 61), or 4 (at codons 117 and 146).

Altogether, the current findings clearly show that RAS mutations in exon 2, 3, or 4 (KRAS G13D mutation is still under debate) represent the most important predictive biomarkers of primary resistance to anti-EGFR therapy in mCRC. For this reason, patients with any known RAS mutation should not be treated with either cetuximab or panitumumab.

**BRAF mutations**

Although it is clear that the RAS status could help identify a patient population that is unlikely to benefit from anti-EGFR therapy, not all patients with tumors containing wild-type RAS respond to treatment with anti-EGFR therapy. Additional molecular alterations in the downstream components of the EGFR signaling network are also likely to associate with resistance to anti-EGFR mAbs. Among these, BRAF, a downstream effector of RAS in the EGFR pathway, has been a subject of focus. Approximately 5% to 9% of CRC harbor BRAF mutations. More than 95% of these mutations occur in the BRAF V600E allele [47]. The BRAF V600E mutation is able to promote tumor cell proliferation and survival by constitutively activation of the mitogen-activated protein kinase (MAPK) signaling pathway (Figure2) [48-50].
Moreover, preclinical and clinical studies have suggested that, regardless of EGFR blockade, mutations in the BRAF V600E can still lead to persistent activation of downstream signaling resulting in cell proliferation and survival [48-50].

It has become clear that the BRAF V600E mutation is a marker of resistance to anti-EGFR therapy in the chemotherapy-refractory setting. A retrospective trial with clinical data from 11 centers in seven European countries analyzed the effect of BRAF mutations on the efficacy of cetuximab plus chemotherapy in patients with chemotherapy-refractory mCRC [17]. This trial concluded that patients with BRAF V600E mutations showed a significantly lower response rate than those with wild type tumors (8.3% vs. 38.0%, OR = 0.15, P = 0.0012). A similar result was demonstrated in a more recent multicenter randomized PICCOLO trial [51]. Taken together, these data suggest that the BRAF V600E mutation contributes to resistance to anti-EGFR moAbs in patients with chemotherapy-refractory KRAS wild-type mCRC. However, observations from first-line therapies are not entirely concordant with this conclusion. In a recent retrospective analysis, Van Cutsem et al. showed that carriers of BRAF mutation gained additional benefit from cetuximab in combination with first-line chemotherapy [5].

To further identify the role of BRAF mutations in the response to EGFR inhibition in patients with mCRC, numerous meta-analyses have been carried out. Of these, one recently published study identified 10 randomized controlled trials (including CRISTAL and OPUS trials) that enrolled 463 patients with BRAF mutations [52]. It shows that the addition of cetuximab or panitumumab treatment did not significantly enhance the benefit of standard therapy or the best supportive care among RAS-wild-type/BRAF-mutated patients in terms of both PFS (HR, 0.88; 95% CI, 0.67-1.14; P = 0.33) and OS (HR, 0.91; 95% CI, 0.62-1.34; P = 0.63). Overall, it suggests that BRAF mutations are in fact associated with resistance to anti-EGFR therapy. Based on these data, a novel combination therapy of BRAF and EGFR inhibitors was administered in patients with BRAF-mutant CRC, and in some of the cases it resulted in improved response rates [53, 54]. These findings therefore, demonstrate a strong causal relationship between the presence of the BRAF V600E mutation and resistance to anti-EGFR therapy in mCRC. We believe that, similar to KRAS, the BRAF V600E mutation could also identify patients that are unlikely to respond to EGFR inhibition. In addition, BRAF mutations are limited to tumors that do not carry the RAS mutation [55]. Therefore, consideration of both BRAF and RAS mutations in tumors before administering anti-EGFR therapy can help identify more than half of the non-responders.

Activations of PIK3CA/PTEN signaling pathway

In addition to the RAS/RAF axis, EGFR also triggers the PIK3CA/PTEN signaling pathway. Both these pathways are major downstream pathways of EGFR and can be blocked by EGFR inhibitors, resulting in tumor cell apoptosis [16]. However, molecular alterations of the PIK3CA/PTEN pathway, including active mutations of PIK3CA or the loss of PTEN expression, can lead to activation of downstream signaling pathways through EGFR-independent mechanisms (Figure 2). Therefore, the role of activated PIK3CA/PTEN signaling in the development of EGFR inhibition resistance has been explored.

Mutations in PIK3CA exon 20

PIK3CA, a catalytic subunit of class I PI3K, encodes the p110α protein kinase, which is a downstream effector of EGFR. Mutations of PIK3CA are reported in approximately 10-18% of mCRC patients and can coexist with both RAS and BRAF mutations [56, 57]. More than 80% of these mutations occur in exon 9 (E542K, E545K) or exon 20 (H1047R) [17]. PIK3CA mutations lead to constitutive activation of the p110α protein kinase and its downstream signaling pathway, thus resulting in tumor cell proliferation and survival.

In mCRC, several studies have evaluated the potential role of PIK3CA mutations as a predictor of resistance to anti-EGFR therapy [21, 58-60]. However, the results of these studies were highly inconsistent. In order to explain these conflicting results, subtle alterations of PIK3CA were explored. Indeed, biochemical studies show that the PIK3CA mutations in exon 9 and exon 20 have different effects. Exon 9 mutations trigger gain of function through RAS-GTP binding, whereas exon 20 mutations do so independent of interaction with RAS-GTP [61]. Thus, it is reasonable to assume that PIK3CA exon 9 and exon 20 mutations may exert different effects upon treatment with anti-EGFR moAbs. In a large retrospective study that investigated the effect of PIK3CA mutations on the response to cetuximab-based therapy [17], the European consortium found that in the KRAS wild-type background, carriers of PIK3CA exon 20 mutations showed significantly lower response rates than carriers of wild-type PIK3CA (0-0% vs. 36.8%; 95% CI 0.00-0.89; P = 0.029), whereas exon 9 mutations showed no significant effect (28.6% vs. 36.3%; 95% CI 0.25-1.78; P = 0.47). Subsequently, the conclusion drawn from a meta-analysis of 13 retrospective cohort studies was that only PIK3CA exon 20 mutations were associated with a lack of response to anti-EGFR MoAbs [62]. Overall, it is clear that PIK3CA exon 9 mutations and exon 20 mutations differ in their predictive power with respect to anti-EGFR therapy responses.

Based on the review of the current literature, it seems that PIK3CA exon 20 mutations are associated with
resistance to anti-EGFR moAbs. However, considering the relatively low frequency of occurrence of these mutations, large randomized clinical trials need to be conducted before definitive conclusions can be drawn.

**PTEN loss**

PTEN negatively regulates the PI3K-AKT signaling pathway through its lipid phosphatase activity, and acts as a tumor suppressor gene. PTEN activity can be lost through either *PTEN* gene silencing or mutation [63]. Loss of PTEN expression is estimated to occur in about 20-40% of patients with mCRC [64]. This loss results in constitutive activation of the PI3K-AKT signaling pathway, leading to tumor cell proliferation and survival.

In breast cancer patients, loss of PTEN protein has been identified as a negative predictor of the efficacy of rastuzumab, an anti-HER2 moAb [65]. However, the role of PTEN loss in CRC remains uncertain. Several studies have reported conflicting and inconclusive results on the impact of PTEN loss on anti-EGFR resistance [59, 66, 67]. For example, Sartore-Bianchi et al. showed in 2009, that PTEN loss is associated with decreased response rate (RR), PFS, and OS in a cohort of 110 patients treated with anti-EGFR moAbs [59]. However, in the same year, Laurent-Puig et al. reported that no significant differences were found in terms of RR, PFS, or OS in association with PTEN expression in a larger patient series [66]. Moreover, another study by Loupakis et al. has confirmed that the data on the loss of PTEN expression are not completely concordant between primary tumors and metastases [67]. In this study, one of 22 patients (5%) with PTEN-negative (detected by the IHC method) metastases responded to cetuximab-based treatment, whereas 12 of 33 patients (36%) with PTEN-positive metastases were partial responders (OR, 12.00; 95% CI, 1.43 to 100.75; P = 0.007). However, such differences with respect to PTEN expression were not observed in primary tumors.

Since there are numerous differences in the analysis of PTEN expression, including IHC scoring algorithms and inconsistent expression in primary and metastatic tumor samples, loss of PTEN expression cannot be reliably regarded as a negative biomarker of the efficacy of anti-EGFR moAbs. Further investigation and prospective large randomized clinical trials are still required to fully confirm the role of PTEN in anti-EGFR therapy resistance.

**Excess activation of JAK/STAT signaling pathway**

The Janus family of tyrosine kinases (JAK) and the signal transducer and activator of transcription (STAT) family are necessary components of cytokine receptor signaling that are actively involved in cellular survival, proliferation, differentiation, and apoptosis. STAT3 is a member of the STAT family of transcription factors that mediate cellular responses to cytokines and growth factors, and is upregulated in many cancers, including CRC [68]. Persistent activation of STAT3, mediated by autocrine and paracrine production of cytokines through the JAK family, as well as activation of tyrosine kinases, such as EGFR and SRC, plays a critical role in oncogenesis, angiogenesis, invasion, metastasis and immune system suppression (Figure 2) [69]. Accumulating evidence supports a role for STAT proteins also in resistance to EGFR inhibitors in several preclinical models, including glioma, head and neck squamous cell carcinoma (HNSCC), and non-small cell lung cancer (NSCLC) [70, 71]. These results provide evidence that STAT3, constitutively activated in CRC, may also play an important role in anti-EGFR treatment resistance.

In a recent study, Qiong Li et al. investigated the mechanism underlying the disappointing effect of the EGFR inhibitor gefitinib in CRC cells, and found that STAT3 phosphorylation (pSTAT3) highly correlated with gefitinib resistance in CRC cells [72]. Their study demonstrates that elevated pSTAT3 levels, mediated by nuclear pyruvate kinase isoform M2 (PKM2), are linked to gefitinib-resistance in CRC cells. Furthermore, inhibition of STAT3 activity by Stattic, a STAT3-specific inhibitor, or STAT3-specific siRNA significantly enhanced the efficacy of gefitinib against CRC cells, both in vitro and in vivo. A similar result was obtained by AS Yar Saglam et al., who demonstrate that combined treatment with cucurbitacin B, a JAK/STAT3 pathway inhibitor, and gefitinib could lead to enhanced antitumor activity in human CRC cells. Therefore, combining EGFR blockade with suppression of JAK/STAT3 signaling is more effective in inhibiting CRC cell growth than inhibition of either pathway alone [73].

These findings suggest that activation of the JAK/STAT3 pathway could contribute to EGFR inhibition resistance in CRC, and targeting the STAT3 pathway may enhance the antitumor effects of EGFR inhibitors and therefore abrogate anti-EGFR therapy resistance.

**Epithelial-to-mesenchymal transition (EMT)**

EMT is a complex biological process wherein epithelial cells procedurally lose their original morphology and simultaneously acquire mesenchymal characteristics [74]. EMT enhances the motility and invasion potential of cells and contributes to a number of cancer-related events, including cancer invasion, metastasis, and treatment resistance [75]. Previous research suggests that the EMT-like transitions that occur in carcinoma cells attenuate the role of EGFR signaling in regulating cell proliferation and survival [76]. These studies consider EMT as a kinase switching mechanism, which, in case of EGFR kinase blockade, leads to signaling activation through alternative tyrosine kinases. Therefore, an EMT-like transition has been implicated as a potential mechanism of anti-EGFR therapy resistance.

In a preclinical analysis, Buck et al. observed a strong correlation between E-cadherin (epithelial marker)
expression and growth inhibition by EGFR inhibitors in CRC cells [77]. Accordingly, epithelial cell lines showed 7-fold more sensitivity to an EGFR inhibitor compared to mesenchymal-like CRC cells. Moreover, the resistance of mesenchymal-like CRC cells to anti-EGFR drugs could be overcome upon combined inhibition of EGFR and CRIPTO, an important signaling node that induces EMT [78]. Overall, the data support a possible role of EMT as a mediator of resistance to anti-EGFR drugs in CRC cells.

However, are cellular mesenchymal-like alterations generated during the course of anti-EGFR treatment, and do they contribute to acquired resistance as well? To answer this question, Sandra Schmitz et al. extended their study to compare pre- and post-cetuximab tumor biopsies for gene and protein expression [79]. As a result, both gene expression profile analysis and quantitative real-time PCR showed significantly increased expression of the known EMT markers LEF1, TWIST1, and ZEB1 in post-treatment biopsies compared with pre-treatment biopsies. This study demonstrates that anti-EGFR treatment could promote EMT, and consequently, contribute to the development of resistance to the treatment itself.

In the phase III randomized TRIBUTE trial, EMT was proven to be related with insensitivity to erlotinib in patients with NSCLC [80]. However, there is no clinical evidence for EMT-induced resistance to EGFR inhibitors in mCRC. Indeed, compared with lung cancer, the current research on EMT-induced resistance in mCRC is very limited. There are still many questions related to EMT-induced resistance in mCRC that need to be answered, such as: 1) What are the mechanisms of EMT-induced resistance? and 2) Can the preclinical studies translate into clinical practice? Although limited data are available for mCRC, we believe that these lacunae will be filled by further evaluation in future studies. Furthermore, an understanding of EMT related resistance to EGFR targeting could provide novel therapeutic opportunities for CRC treatment.

**ACQUIRED RESISTANCE TO ANTI-EGFR THERAPY IN CRC**

Nearly all patients with mCRC that initially respond to EGFR monoclonal antibodies eventually show disease progression. This progression upon anti-EGFR therapy is known as acquired resistance. Clinical data indicate that response to anti-EGFR therapies is relatively short-lived and most tumors become refractory within 3-12 months [81]. It is therefore conceivable that numerous mechanisms might contribute to this acquired resistance to anti-EGFR antibodies.

**Secondary alterations in the RAS/RAF signaling pathway**

The RAS/RAF signaling axis is one of the most important downstream signaling pathways of EGFR and has been highlighted by its role in primary resistance to anti-EGFR therapy in mCRC. Indeed, genetic alterations in RAS/RAF signaling are also the most common molecular mechanism that drives secondary resistance.

KRAS mutations, in addition to being a key driver of primary resistance to anti-EGFR antibodies in CRC, play a vital role in acquired resistance as well. Approximately 50% of acquired resistance cases occur due to secondary KRAS mutations [82, 83]. Both pre-clinical models and clinical samples have proven that the emergence of KRAS mutations is a mediator of acquired resistance to EGFR inhibitors. In 2010, Bouchahda et al. reported the first case of CRC liver metastasis, wherein tumor KRAS mutations were detected after the development of resistance to cetuximab [84]. In this case, no KRAS mutation was detected in the primary or metastatic tumor samples before the beginning of the cetuximab treatment. However, upon cetuximab treatment, further liver relapse occurred, and two KRAS mutations at codon 13 and 12 were detected in the metachronous liver metastatic tissues. A similar study was subsequently performed by Misale et al., who analyzed the molecular profiles of relapsed tumors from CRC patients [83]. Six of the 10 patients that were KRAS wild type prior to treatment showed KRAS mutations in their plasma samples while receiving cetuximab. In contrast, KRAS mutations were not detected in patients who underwent chemotherapy alone. Interestingly, in the same study, Misale et al. also found one relapsed case, where the patient receiving anti-EGFR moAbs exhibited KRAS amplification, which is an otherwise infrequent event in CRC. It is therefore clear that the emergence of KRAS mutations and KRAS amplification is associated with acquired resistance to EGFR inhibitors. Likewise, secondary mutations in NRAS and BRAF are also associated with secondary resistance. For instance, in a preclinical model, cetuximab- and/or panitumumab-resistant CRC cell lines, initially sensitive to anti-EGFR moAbs, developed resistance after continuous anti-EGFR treatment. Strikingly, in addition to the alterations at the known hotspots of the KRAS gene, NRAS and BRAF mutations were also found in the resistant populations and also in some cell lines harboring multiple mutations [85]. However, this emergence of “acquired genetic alterations” in RAS/RAF signaling raises the question of whether these alterations are novel spontaneous mutations or whether they are selected from pre-existing resistant subclones by the anti-EGFR therapy. Misale et al. and Diaz et al. addressed this question following different approaches, either *in vitro* or *in vivo* [82, 83]. Strikingly, both groups arrived at a similar explanation namely, that “acquired” alterations in KRAS could be an expansion of
Table 1: Genetic and histologic evidence for resistance to anti-EGFR drugs in CRC.

| Reference/study | Patients included in analysis, n | Study type | Genetic and histologic evidence |
|-----------------|---------------------------------|------------|--------------------------------|
| **Low EGFR gene copy number** | | | |
| Moroni et al. [22] | 31 | Clinical study | Low EGFR gene copy number was significantly associated with non-response after treatment with cetuximab or panitumumab (with or without chemotherapy). Low EGFR gene copy number was significantly associated with non-response and shorter PFS and OS after treatment with panitumumab. |
| Sartore-Bianchi et al. [27] | 92 | Clinical study | |
| **Low expression of AREG and EREG** | | | |
| Khambata-Ford et al. [23] | 110 | Clinical study | Low expression of AREG and EREG was significantly associated with non-response and shorter PFS and OS after treatment with cetuximab. Low expression of AREG and EREG was significantly associated with non-response and shorter PFS and OS after treatment with cetuximab plus irinotecan. |
| Jacobs et al. [31] | 220 | Clinical study | |
| **EGFR S492R mutation** | | | |
| Montagut et al. [109] | 10 | Preclinical and clinical study | Acquired EGFR ectodomain mutation (S492R) prevents cetuximab binding and confers resistance to cetuximab in human mCRC cell line DiFi. Two of ten individuals with mCRC with disease progression after cetuximab treatment acquired S492R mutation. |
| **RAS mutation** | | | |
| Allegra et al. [37]a | - | Clinical study | KRAS exon 2 (codon 12 and 13) mutations were significantly associated with non-response and shorter PFS and OS in mCRC patients treated with cetuximab or panitumumab (with or without chemotherapy). RAS mutations in exons 2 (codons 12 and 13), 3 (codons 59 and 61), and 4 (codons 117 and 146) of both KRAS and NRAS were associated with non-response and shorter PFS and OS in mCRC patients treated with cetuximab or panitumumab (with or without chemotherapy). |
| Allegra et al. [35]b | - | Clinical study | |
| **BRAF V600E mutation** | | | |
| De Roock et al. [17] | 1022 | Clinical study | BRAF V600E mutation was significantly associated with a low RR in mCRC patients treated with cetuximab plus chemotherapy. BRAF mutation was significantly associated with shorter PFS and OS after treatment with cetuximab or panitumumab (with or without chemotherapy). |
| Rowland et al. [52] | 463 | Meta-analysis | |
| **PIK3CA exon 20 mutation** | | | |
| De Roock et al. [17] | 1022 | Clinical study | PIK3CA exon 20 mutations were significantly associated with non-response and shorter PFS and OS after treatment with cetuximab plus chemotherapy. |
| **PTEN loss** | | | |
| Sartore-Bianchi et al. [59] | 110 | Clinical study | PTEN loss was significantly associated with decreased RR, PFS, and OS in mCRC patients treated with panitumumab or cetuximab (with or without chemotherapy). PTEN expression was not significantly associated with RR, PFS, or OS in mCRC patients treated with cetuximab plus chemotherapy. |
| Laurent-Puig et al. [66] | 102 | Clinical study | |
| **STAT3 phosphorylation** | | | |
| Li et al. [72] | - | Preclinical study | Elevated phospho-STAT3 levels correlate with geftinib resistance in CRC cells and are regulated by nuclear PKM2. |
| **Activated IGF1R** | | | |
pre-existing resistant clones under the pressure of anti-EGFR moAbs. Furthermore, given the existence of inter- and intra-tumor heterogeneity, the explanation of latent resistant clones seems more convincing. In conclusion, acquired RAS and BRAF genetic alterations have been identified as a mechanism of acquired resistance to anti-EGFR therapy in CRC and these genetic alterations most likely arise because of clonal selection of pre-existing resistant cells.

**Activation of alternative growth factor receptor pathways**

The other major mechanism of acquired resistance to anti-EGFR moAbs is the activation of growth-factor signaling pathways by upregulation of alternative and compensatory signaling cascades through receptors other than EGFR. For example, numerous growth factor receptors, such as type 1 insulin-like growth factor receptor (IGF-1R), mesenchymal-epithelial transition factor receptor (MET receptor), and the human epidermal growth factor receptor-2 (HER2) [86-88], can activate EGFR downstream effectors and trigger the ensuing intracellular signaling pathways by bypassing EGFR, thus inducing tumor cell proliferation and resistance to apoptosis (Figure 3).

**Activation of the IGF-1R pathway**

IGF-1R belongs to a family of transmembrane tyrosine kinases. IGF-1R is activated upon insulin-like growth factor (IGF) 1 or IGF-2 binding, and leads to downstream activation of the RAS/RAF/MAPK and PI3K/AKT pathways [86, 89]. In addition, strong molecular cross talk between the IGF-1R and EGFR networks has been demonstrated during recent years. Preclinical studies have shown that activated signaling through IGF-1R leads to increased activation of EGFR [90-92]. Therefore, the effect of anti-EGFR therapy may be bypassed through the activation of alternative, IGF-1R-induced pathways. For instance, in breast cancer, increased activation of the IGF-1R/PI3K/AKT pathway has been found in an anti-EGFR agents and linked with acquired resistance to anti-EGFR moAbs [93]. Similarly, recent studies have implicated
IGF-1R and its ligands (IGF-1/IGF-2) in acquired resistance to anti-EGFR therapy in CRC [92, 94]. In a retrospective study of 168 patients with KRAS wild-type mCRC, the expression of IGF1 was evaluated in terms of clinical outcome in patients treated with irinotecan and cetuximab [94]. The result showed that a numerically lower response rate (22% vs. 65%; HR, 4.2; 95% CI, 2.0-10.2; \( P = 0.003 \)) was seen in IGF-1-positive groups compared to IGF-1-negative groups. This significant difference demonstrates that increased activation of the IGF-1R pathway is correlated with resistance to anti-EGFR therapy.

As a potential biomarker of resistance to anti-EGFR agents, IGF-1R has recently emerged as an attractive therapeutic target. Preclinical data have demonstrated that combined inhibition of IGF-1R and EGFR resulted in an enhanced anti-tumor effect in xenograft models [95]. Although in numerous early clinical analyses neither IGF1R inhibitors alone nor the combination with anti-EGFR moAbs showed any promising anti-tumor activity in patients with anti-EGFR moAb-refractory mCRC [96], in a more recent randomized phase II/III study, a response to the IGF-1R inhibitor was identified by further exploratory biomarker analyses [97]. In this study, 344 eligible patients with KRAS wild-type tumors were randomly assigned to dalotuzumab (IGF1R inhibitor) or placebo in combination with cetuximab and irinotecan. The results showed that the addition of dalotuzumab did not improve PFS or OS compared to the placebo group. However, when the effect of the treatment was further evaluated with respect to IGF-1 expression, improvements in PFS (5.6 vs. 3.6 months; HR = 0.59; 95% CI = 0.28 to 1.23; \( P = 0.16 \)) and OS (17.9 vs. 9.4 months; HR = 0.67; 95% CI = 0.31 to 1.45; \( P = 0.31 \)) were observed in IGF-1 positive tumors compared to IGF-1 negative tumors when dalotuzumab was added. In contrast, the placebo group showed shorter PFS (3.6 vs. 6.6 months; HR = 2.15; 95% CI = 1.15 to 4.02; \( P = 0.02 \)), and OS (9.4 vs. 15.5 months; HR = 2.1; 95% CI = 1.21 to 4.82; \( P = 0.01 \)) in patients with IGF-1 positive tumors. These synergistic anti-tumor effects further support a role for IGF-1R as a mediator of resistance to anti-EGFR agents.

In conclusion, the IGF system has been attributed an important role in the mechanisms of anti-EGFR therapy resistance in CRC. However, in order to establish the reliable use of IGF1R inhibitors in specific anti-EGFR resistant patients a more comprehensive analysis of the existing data is required.

MET overexpression and amplification

The MET oncogene encodes the tyrosine kinase receptor for Hepatocyte Growth Factor (HGF) and leads to cell proliferation and survival through the activation of intracellular signaling cascades including the PI3K/AKT, RAC1/cell division control protein 42 (CDC42), RAP1 and RAS/MAPK pathways [98]. In NSCLC, activation of MET/PI3K/AKT signaling has been identified as one of the key compensatory pathways to escape the inhibitory effects of the EGFR TKI gefitinib [99, 100]. Moreover, a complex cross-signaling network between EGFR and MET has also emerged in the past few years [98, 101]. EGFR-MET interactions with subsequent activation of the MET pathway induced by the overexpression of TGF-α have been proposed to be a probable mechanism for acquired resistance to cetuximab in CRC cells [101]. These results highlight a possible role for MET in mediating resistance to anti-EGFR therapies in CRC. Indeed, in 2011, Liska et al. demonstrated that HGF-induced MET activation could confer cetuximab resistance to CRC cells [102]. In particular, they showed that HGF-mediated MET activation could rescue CRC cells from cetuximab-induced apoptosis or cell cycle arrest by restoring signaling through the AKT and MAPK pathways. Interestingly, further analysis showed that the effects of cetuximab could again be restored by both pharmacological inhibition and silencing of MET [102].

Furthermore, in an in vivo study, analysis of tumor tissues from patients who developed resistance to cetuximab or panitumumab showed the emergence of MET amplification in more than 40% (3 out of 7) of the cases [87]. Additionally, MET amplification was rarely found in pre-treatment tumor tissues. Only one of the three cases with post-treatment MET amplification revealed a rare MET amplification in the pre-treatment samples as well. In conclusion, the emergence of MET amplification correlates with acquired resistance to anti-EGFR therapies in CRC, and possibly arises from an expansion of pre-existing MET amplified clones under the pressure of anti-EGFR therapy.

Notably, MET amplification could also be responsible for primary resistance to anti-EGFR moAbs in CRC. Data obtained from both patient samples and xenografts have identified that amplification of MET correlates with a negative response to cetuximab [87, 103]. However, MET amplification was found only in about 1% of untreated mCRC cases [87]. For this reason, MET amplification cannot be reliably considered as a biomarker of primary resistance to anti-EGFR therapy in mCRC.

HER2 amplification and overexpression of the HER3/4 ligand heregulin

HER2 is a member of the HER family of receptor tyrosine kinases that has the ability to activate the MAPK and PI3K/AKT pathways through heterodimerisation with EGFR or HER3 [88, 104]. HER2 leads to the activation of a signaling pathway shared with EGFR and is therefore, a potential biomarker of resistance to anti-EGFR therapy.

In an early analysis, Bertotti et al. took advantage of a large collection of patient-derived mCRC xenografts (‘xenopatients’) to assess the role of the HER2 gene in cetuximab resistance [105]. Analysis of genotype-response correlations in HER2-amplified xenopatients demonstrated
that HER2 gene amplification was specifically related to cetuximab resistance. In addition, this resistance could be overcome through the administration of a HER2 inhibitor. However, a later study by Yonesaka et al. did not completely agree with these findings [104]. Yonesaka et al. found that the effect of HER2 in the resistance to anti-EGFR moAbs was not only limited to the amplification of the receptor, but also to the secretion of the ligand heregulin. In their study with clinical samples, patients with HER2 gene amplification or overexpression of the HER3/4 ligand heregulin were associated with a significantly poorer PFS and OS. Furthermore, both of these mechanisms could lead to persistent activation of ERK signaling, thus circumventing the anti-tumor effects of anti-EGFR therapy. Both Bertotti et al. and Yonesaka et al. suggested a synergistic anti-tumor effect of the combined inhibition of HER2 and EGFR. Their studies demonstrated that combinations of selective inhibitors targeting HER2 and EGFR were able to significantly inhibit the growth of cetuximab-resistant CRC cells, and induce long-lasting tumor regression in experimental models [104, 105]. These results not only emphasized HER2 gene amplification and heregulin overexpression as important mechanisms of resistance to anti-EGFR therapy, but also highlighted a possible new therapeutic target for clinical use.

Indeed, HER2 amplification has been suggested as both an intrinsic, as well as an acquired mechanism of resistance. However, it should be stressed that the prevalence of HER2 amplification is infrequent in CRC, and occurs only in about 2% of unselected mCRC [104, 106]. Therefore, considering its low frequency, HER2 amplification is not likely to be a key player in primary resistance to anti-EGFR therapy. On the other hand, pre-existing infrequent HER2-amplified clones might be expanded under the selective pressure of anti-EGFR therapy, leading to disease progression. In this regard, HER2 amplification is more likely to confer acquired anti-EGFR therapy resistance.

**EGFR S492R mutation**

It is well known that the T790M mutation of EGFR plays a critical role in acquired resistance to EGFR TKIs in NSCLC. Statistically, more than half of NSCLC patients with acquired resistance to TKIs were found to carry the EGFR T790M mutation [107, 108]. It is thus anticipated that secondary mutations in EGFR might also lead to resistance against anti-EGFR moAbs in CRC. In fact, in 2011, Montagut and colleagues discovered an acquired mutation in the extracellular domain of EGFR (S492R) and proved its association with acquired resistance to cetuximab in mCRC [109]. In an analysis of ten patients

Table 2: Overview of molecular mechanism of resistance and putative strategy to overcome resistance

| Genetic alterations       | Primary resistance | Acquired resistance | Possible strategy to overcome resistance                                                                 | Reference |
|---------------------------|--------------------|---------------------|----------------------------------------------------------------------------------------------------------|-----------|
| Altered EGFR             | Yes                | Yes                 | MEK inhibitors with PI3K inhibitors or mTOR inhibitors; Panitumumaba (EGFR S492R mutation)                | [109, 119]|
| RAS mutation             | Yes                | Yes                 | Anti-EGFR with MEK inhibitors                                                                           |           |
| BRAF V600E mutation      | Yes                | Yes                 | Anti-EGFR with BRAF inhibitors or MEK inhibitors                                                          | [54, 118, 122]|
| PIK3CA exon 20 mutation  | Yes                | Not Sure            | Anti-EGFR with PI3K inhibitors or mTOR inhibitors                                                         | [119, 120]|
| PTEN loss                | Not Sure           | Not Sure            | Anti-EGFR with PI3K inhibitors or mTOR inhibitors                                                         | [119, 120]|
| STAT3 phosphorylation    | Yes                | Yes                 | Anti-EGFR with STAT3 inhibitors                                                                           | [72, 73]  |
| Activated IGF1R          | Minor Effect       | Yes                 | Anti-EGFR with IGF1R inhibitors                                                                          | [97]      |
| MET amplification        | Minor Effect       | Yes                 | Anti-EGFR with MET inhibitors                                                                           | [98]      |
| HER2 amplification       | Minor Effect       | Yes                 | Anti-EGFR with HER2 inhibitors                                                                            | [105, 121]|
| Altered VEGF/VEGFR       | No                 | Yes                 | Anti-EGFR with anti-VEGF or anti-VEGFR                                                                  | [113]     |

**Abbreviation** MEK: (also called MAP2K) mitogen-activated protein kinase kinase, mTOR: mammalian target of rapamycin.

**Superscript** a: treatment with panitumumab is a rational strategy to overcome cetuximab resistance caused by the EGFR S492R mutation.
that showed disease progression after cetuximab treatment, two patients were detected with the S492R mutation. Moreover, mutations at this site were not detected in their pre-treatment biopsies. *In vitro* findings in a cetuximab-resistant CRC cell model showed a similar result.

Further analysis indicated that the substitution of serine to arginine at amino acid 492 (S492R) is caused either by the 1476C > A or the 1474A > C mutation in the gene region encoding for the extracellular domain of EGFR [109]. This mutation reduces the affinity of the receptor to the ligand and interferes with binding to cetuximab. Notably, the S492R mutation does not inhibit binding of panitumumab to EGFR. Indeed, in the study by Montagut et al., one of the two cetuximab-resistant patients with tumors harboring the S492R mutation responded to subsequent treatment with panitumumab. Therefore, following disease progression upon cetuximab treatment, treatment with panitumumab appears to be a rational strategy for patients harboring the S492R mutation.

Strikingly, in the same study, the S492R EGFR mutation was not detected in any of the tumor samples collected from 156 mCRC patients that did not undergo any therapy. Esposito et al. obtained the same result in a larger cohort of patients [110]. Overall, these findings strongly identified the S492R mutation as a mechanism of acquired but not primary resistance to cetuximab.

**Alteration of VEGF signaling**

Vascular endothelial growth factor (VEGF) is a potent signaling molecule that plays a central role in angiogenesis. VEGF binds to and activates three structurally similar receptor tyrosine kinases: VEGFR1 (also known as FLT1), VEGFR2 (also known as KDR), and VEGFR3 (also known as FLT4) [111]. These receptors primarily mediate changes within vasculature, including endothelial cell proliferation and permeability. In addition, VEGF signaling has several important functions that are independent of neovascularization, such as effects on tumor cell survival, migration, and invasion (Figure 3) [112].

Furthermore, aberrant VEGF signaling has been shown to be associated with acquired EGFR inhibitor resistance. Ciardiello et al. demonstrated ten years ago, that elevated expression of VEGF in colon cancer cells was correlated with the resistance to the EGFR inhibitor [113]. In addition, a more recent study by Bianco et al. showed that VEGF, as well as VEGFR1 were secreted at higher levels in cetuximab-resistant cells than in the parental cetuximab-sensitive cells [114]. Moreover, the growth and migration of EGFR inhibitor-resistant cells could be inhibited by VEGFR1 silencing or by vandetanib, an orally available TKI that inhibits EGFR, VEGFR1, and VEGFR-2 tyrosine kinases. These findings indicate that the combined inhibition of VEGFR and EGFR results in restoration of sensitivity to anti-EGFR drugs, and further supports an association between increased expression of VEGF/VEGFR1 and anti-EGFR treatment resistance.

Overall, preclinical experiments have demonstrated that VEGF signaling plays an important role in anti-EGFR therapy resistance and the combination of VEGFR and EGFR inhibitors has been associated with improved anti-tumor activity in xenografts [113]. For these reasons, it was assumed that blockade of VEGF signaling pathway could be a way to overcome anti-EGFR therapy resistance. However, this putative preclinical strategy was not successful in the clinic [115-117]. In the CAIRO2 and PACCE clinical trials, the combination of the anti-VEGF moAb bevacizumab, and the anti-EGFR moAb cetuximab or panitumumab did not result in improved PFS or OS [115, 116]. These results raise the possibility of a negative interaction between anti-EGFR moAbs and anti-VEGF moAbs when combined with chemotherapy in clinical practice. An increase in drug related toxicity is a likely cause of the reduction in survival, since it contributed to increases in dose delays, decreases in dose intensity, and increases in mortality in the dual EGFR/VEGF inhibition arm. In addition, several studies suggest that there potentially exists a negative pharmacodynamic interaction between anti-EGFR moAbs and anti-VEGF moAbs [116]. Therefore, further research is still required in order to develop a more comprehensive understanding of the role of VEGF signaling in the resistance of anti-EGFR therapy.

**OVERCOMING RESISTANCE TO ANTI-EGFR THERAPY**

It is clear that aberrant biomarkers, including RAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, STAT3 phosphorylation, IGF1R activation, *MET* amplification, *HER-2* amplification, and altered VEGF and VEGFR signaling (Table 1) result in resistance to anti-EGFR therapy mainly through constitutive activation of EGFR downstream signaling pathways regardless of EGFR blockade. Consequently, it is reasonable to anticipate that knockdown or inhibition of the resistance pathways will be an effective way to restore sensitivity to EGFR inhibition.

Therefore, a rational approach to block the resistance pathways is simultaneous or sequential targeting of the aberrant biomarkers. Indeed, for almost all the biomarkers that are correlated with resistance, there is already a promising targeted strategy proposed either in preclinical studies or in clinical trials (Table 2). Sorafenib, a potent inhibitor of the V600E B-RAF protein, which is also a well-known multi-targeted kinase inhibitor, has shown pronounced activity in combination with cetuximab in V600E BRAF-mutant CRC cells [118]. In this study, Di Nicolantonio et al. showed that treatment with cetuximab alone was less effective in V600E BRAF-mutant cells than in BRAF-wild-type cells. However, sensitivity
It is apparent that multiple mechanisms of anti-EGFR therapy resistance exist in CRC, which range from molecular alterations to histological transformations (Table 1). Most of them act individually or in concert to counteract the activity of anti-EGFR drugs. However, resistance to anti-EGFR mAbs is mainly mediated through the constitutive activation of EGFR downstream signaling cascades that can result from either genetic alterations in the members of RAS/RAF, PIK3CA/PTEN, and JAK/STAT pathways (Figure 2) or from the activation of alternative growth factor receptors, such as IGF1R, HER2, and MET (Figure 3). Altogether, these primary mechanisms of resistance account for over 70% of the cases that are unresponsive to anti-EGFR therapies [87].

Although these data are exciting and open new approaches for selecting patients likely to develop insensitivity to anti-EGFR drugs, only RAS mutations are currently approved for clinical consideration. Therefore, numerous retrospective and prospective clinical trials are required to assess whether research on other biomarkers can be translated into effective clinical practice. At the same time, a comprehensive understanding of resistance mechanisms through studies in both preclinical models and CRC patients, will ultimately lead to the development of more effective targeted strategies. Our current understanding of the mechanisms of resistance to anti-EGFR therapies is not yet complete, as additional resistance mechanisms may be undiscovered. As the field of molecular targeting treatment continues to evolve, a more comprehensive picture of resistance mechanisms will be formed, which will help the development of novel strategies to overcome both primary and acquired resistance.

ACKNOWLEDGMENTS AND FUNDING

This work was supported by the National Natural Science Foundation of China (Grant No. 81472921, and 81372664).

CONFLICTS OF INTEREST

No potential conflicts of interest were disclosed.

REFERENCES

1. Siegel R, Desantis C, and Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 104-17. doi: 10.3322/caac.21220.
2. Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, and Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014; 4: 1269-80. doi: 10.1158/2159-8290.CD-14-0462.
3. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, and Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011; 22: 1535-46. doi: 10.1093/annonc/mdq632.
4. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendliasz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, and Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25: 1658-64. doi: 10.1200/JCO.2006.08.1620.
5. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascini S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29: 2011-9. doi: 10.1200/JCO.2010.33.5091.

6. Tveit KM, Guren T, Glimeilius B, Pfeiffer P, Sorbye H, Pyrhouen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofstri F, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012; 30: 1755-62. doi: 10.1200/JCO.2011.38.0915.

7. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziasczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011; 377: 2103-14. doi: 10.1016/S0140-6736(11)60613-2.

8. Van Cutsem E, Kohne CH, Hitre E, Zaluzki J, Chien CR, Makhson A, D’Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-17. doi: 10.1056/NEJMoa0805019.

9. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Van Cutsem E, Kohne CH, Lang I, Folprecht G, Ruff P, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010; 28: 4697-705. doi: 10.1200/JCO.2009.27.4860.

10. Meyerhardt JA, and Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005; 352: 476-87. doi: 10.1056/NEJMra040958.

11. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, and Go WY. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014; 32: 2240-7. doi: 10.1200/JCO.2013.53.2473.

12. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, Seipel G, Kullmann F, Stauch M, Scheithauer W, et al. FOLFIIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15: 1065-75. doi: 10.1016/S1470-2045(14)70330-4.

13. Lenz H, Niedzwiecki D, Innocenti F, Blanke C, Mahony MR, O’Neil BH, Shaw JE, Polite B, Hochster H, Atkins J, Goldberg R, Mayer R, Schilsky RL, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or of oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (mCRC): expanded RAS analyses. Ann Oncol. 2014; 25: abstract 5010.

14. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999; 82: 241-50. doi: 10.1016/S0163-7258(98)00045-X.

15. Yarden Y, and Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127-37. doi: 10.1038/35052073.

16. Ciardiello F, and Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358: 1160-74. doi: 10.1056/NEJMra0707704.

17. De Roock W, Claes B, Bernasconi D, De Schutter J, De Roock W, Van Cutsem E, Claes B, Bernasconi D, De Schutter J, et al. KRAS and BRAF mutations in colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-62. doi: 10.1016/S1470-2045(10)70130-3.

18. Hsu HC, Thiam TK, Lu YJ, Yeh CY, Tsai WS, You JF, Hung HY, Tsai CN, Hsu A, Chen HC, Chen SJ, and Yang TS. Mutations of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Oncotarget. 2016; 7: 22257-70. doi: 10.18632/oncotarget.8076.

19. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, and Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer patients. Oncotarget. 2016; 7: 22257-70. doi: 10.18632/oncotarget.8076.

20. Bardelli A, and Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010; 28: 1254-61. doi: 10.1200/JCO.2009.24.6116.

21. Roock WD, Frientd VD, Normanno N, Ciardiello F, and Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. The Lancet Oncology. 2011; 12: 594-603. doi: 10.1016/s1470-2045(10)70209-6.

22. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, and Bardelli A. Gene copy number for epidermal growth factor receptor as a predictor of survival in patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15: 1065-75. doi: 10.1016/S1470-2045(14)70330-4.
growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. The Lancet Oncology. 2005; 6: 279-86. doi: 10.1016/s1470-2045(05)70102-9.

23. Kambata-Ford S, Garrett CR, Meropol N, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, 3rd, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007; 25: 3230-7. doi: 10.1200/JCO.2006.10.5437.

24. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-39. doi: 10.1056/NEJMoa040938.

25. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, and Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 719-26. doi: 10.1200/JCO.2002.20.3.719.

26. Barber TD, Vogelstein B, Kinzler KW, and Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med. 2004; 351: 2883. doi: 10.1056/NEJM200412303512724.

27. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Causini S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol. 2007; 25: 3238-45. doi: 10.1200/JCO.2006.10.5437.

28. Yang ZY, Shen WX, Hu XF, Zheng DY, Wu XY, Huang YF, Chen JZ, Mao C, and Tang JL. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis. J Hematol Oncol. 2012; 5: 52. doi: 10.1186/1756-8722-5-52.

29. Personeni N, Fieuws S, Piessevaux H, De Schutter J, Biesmans B, De Roock W, Capoen A, Debiec-Rychter M, Van Laethem JL, Peeters M, Humblet Y, Pauwels-Llorca F, De Hertogh G, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2009; 27: 5068-74. doi: 10.1200/JCO.2008.21.3744.

30. Malumbres M, and Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003; 3: 459-65. doi: 10.1038/nrc1097.

31. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989; 49: 4682-9.

32. Fernandez-Medarde A, and Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011; 2: 344-58. doi: 10.1177/1947601911411084.

33. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989; 49: 4682-9.

34. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Mangu PB, Roach N, Hantel A, and Schilsky RL. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016; 34: 179-85. doi: 10.1200/JCO.2015.63.9674.

35. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, and Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 1626-34. doi: 10.1200/JCO.2007.14.7116.

36. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, and Schilsky RL. American Society of Clinical Oncology Provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal cancer to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27: 2091-6. doi: 10.1200/JCO.2009.21.9170.

37. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O’Callaghan CJ, Kambata-Ford S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. JAMA. 2010; 304: 1812-20. doi: 10.1001/jama.2010.1535.

38. Teijpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, and Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 2012; 30: 3570-7. doi: 10.1200/JCO.2012.42.2592.

39. Gajate P, Sastre J, Bando I, Alonso T, Cillero L, Sanz J, Caldes T, and Diaz-Rubio E. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer
treated with cetuximab. Clin Colorectal Cancer. 2012; 11: 291-6. doi: 10.1016/j.ccc.2012.02.003.
41. Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, and Wiezorek J. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol. 2013; 31: 759-65. doi: 10.1200/JCO.2012.45.1492.
42. Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duerck K, and Tejpar S. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/ without cetuximab. J Clin Oncol. 2014; 32(5s): abstract 3505.
43. Ciardiello F, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, Beier F, Stroh C, and EV. C. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol. 2014; 32: abstract 3506.
44. Douillard JY, Oliner KS, Siena S, Tabernero J, Burke R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369: 1023-34. doi: 10.1056/NEJMoia1305275.
45. Stintzing S, Jung A, Rossius L, Modest DP, Fischer von Weikerthal L, Decker T, Kiani A, Möhler M, Kirchner T, and Heinemann V. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Eur J Cancer. 2014; 49: abstract LBA-17.
46. Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, Beier F, Stroh C, Rougier P, van Krieken JH, and Ciardiello F. Fluorouracil, leucovorin, and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013; 14: 749-59. doi: 10.1016/S1470-2045(13)70163-3.
47. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013; 14: 749-59. doi: 10.1016/S1470-2045(13)70163-3.
48. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dickens E, Ewing R, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 418: 949-54. doi: 10.1038/418934a.
49. Nosho K, Kawasaki T, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, and Ogino S. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008; 10: 534-41. doi: 10.1593/neo.080336.
50. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lovie A, Cortet M, Bouvier AM, Rat P, Roignot P, Faivre J, Laurent-Puig P, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer. 2008; 122: 2255-9. doi: 10.1002/ijc.23388.
51. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2009; 20: 84-90. doi: 10.1093/annonc/mdn541.
52. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, and Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002; 418: 934. doi: 10.1038/418934a.
53. Al-Marrawi MY, Saroya BS, Brennan MC, Yang Z, Dykes TM, and El-Deirwis YS. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colorectal cancer. Cancer Biol Ther. 2014; 15: 826-31. doi: 10.4161/cbt.28878.
54. Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K, Kawakami T, Aragaki J, Matsumura M, Kawabe T, et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res. 2003; 63: 8132-7.
S, Michelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, and Bardelli A. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009; 69: 1851-7. doi: 10.1158/0008-5472.CAN-08-2466.

60. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, and Tejpar S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res. 2009; 15: 3184-8. doi: 10.1158/1078-0432.CCR-08-2961.

61. Zhao L, and Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A. 2008; 105: 2652-7. doi: 10.1073/pnas.0712169105.

62. Mao C, Yang ZY, Hu XF, Chen Q, and Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2012; 23: 1518-25. doi: 10.1093/annonc/mdr464.

63. Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wassermon L, Compton C, Mayer RJ, Bertagnolli MM, and Boland CR. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004; 64: 3014-21. doi: 10.1158/0008-5472.CAN-04-1825.

64. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, and Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009; 101: 1308-24. doi: 10.1093/jnci/djp280.

65. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hertogbagi GN, Hung MC, and Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6: 117-27. doi: 10.1016/j.ccc.2004.06.022.

66. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Yehou M, Bibeau F, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009; 27: 5924-30. doi: 10.1200/JCO.2008.21.6796.

67. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Maso G, Graziano F, Creminelli C, Rulli E, Canestra E, Funel N, Schiavon G, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol. 2009; 27: 2622-9. doi: 10.1200/JCO.2008.20.2796.

68. Ma XT, Wang S, Ye YJ, Du RY, Cui ZR, and Somsouk M. Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol. 2004; 10: 1569-73.

69. Kisseleva T, Bhattacharya S, Braunstein J, and Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002; 285: 1-24. doi: 10.1016/S0378-1119(02)00398-0.

70. Kijima T, Niwa H, Steinman RA, Dreming SD, Gooding WE, Wentzel AL, Xi S, and Grandis JR. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ. 2002; 13: 355-62.

71. Haura EB, Sommers E, Song L, Chiappori A, and Becker A. A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol. 2010; 5: 1806-14. doi: 10.1097/JTO.0b013e3181f87f07.

72. Li Q, Zhang D, Chen X, He L, Li T, Xu X, and Li M. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer. Sci Rep. 2015; 5: 16082. doi: 10.1038/srep16082.

73. Yar Saglam AS, Alp E, Elzamzoglu Z, and Menevse S. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines. Hum Exp Toxicol. 2016; 35: 526-43. doi: 10.1177/0960327115595686.

74. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-54. doi: 10.1038/nrc822.

75. Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY, and Thiery JP. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med. 2014; 6: 1279-93. doi: 10.15252/emmm.201404208.

76. Thomson S, Petti F, Sujka-Kwok I, Epstein D, and Haley JD. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis. 2008; 25: 843-54. doi: 10.1007/s10432-008-9200-4.

77. Buck E, Eyzaquiur A, Barr S, Thompson S, Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P, and Haley JD. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther. 2009; 8: 532-41. doi: 10.1158/1535-7163.MCT-06-0462.

78. De Luca A, Arra C, D’Antonio A, Casamassimi A, Losito S, Ferraro P, Ciardiello F, Salomon DS, and Normanno N. Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene. 2000; 19: 5863-71.

79. Schmitz S, Bindea G, Albu RI, Mlecnik B, and Machiels JP. Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst. 2015; 107: 327-36. doi: 10.1093/jnci/dju002.
80. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O’Neill V, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res. 2005; 11: 8686-98. doi: 10.1186/1078-0432.CCR-05-1492.

81. Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, and Bardelli A. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol. 2014; 8: 1084-94. doi: 10.1016/j.molonc.2014.05.003.

82. Diaz LA, Jr., Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Olner KS, and Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature; 2012; 486: 537-40. doi: 10.1038/nature11219.

83. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature; 2012; 486: 532-6. doi: 10.1038/nature11156.

84. Bouchahda M, Karaboue A, Saffroy R, Innominato P, Gorden L, Guettier C, Adam R, and Levi F. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol. 2010; 66: 605-9. doi: 10.1007/s00028-010-1298-9.

85. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to targeted EGFR therapies in colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer. 2010; 127: 1941-7. doi: 10.1002/ijc.25193.

86. Bouchahda M, Karaboue A, Saffroy R, Innominato P, Gorden L, Guettier C, Adam R, and Levi F. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol. 2010; 66: 605-9. doi: 10.1007/s00028-010-1298-9.

87. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to targeted EGFR therapies in colorectal cancer. Nature; 2012; 486: 537-40. doi: 10.1038/nature11219.

88. Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D, and Baretton GB. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer. 2002; 98: 1152-9. doi: 10.1002/cncr.10759.

89. Yu H, and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000; 92: 1472-89. doi: 10.1093/jnci/92.18.1472.

90. Hu YP, Patil SB, Panasiewicz M, Li W, Hauser J, Humphrey LE, and Brattain MG. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Res. 2008; 68: 8004-13. doi: 10.1158/0008-5472.CAN-08-0280.

91. Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, and Nicholson RI. Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer. 2006; 13 Suppl 1: S45-51. doi: 10.1677/erc.1.01275.

92. Scartozzi M, Mandolesi A, Giampieri R, Pierantonio C, Loupakis F, Zaniboni A, Galizia E, Giustini L, Silva RR, Bisonni R, Berardi R, Biagetti S, Menzo S, et al. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer. 2010; 127: 1941-7. doi: 10.1002/ijc.25193.

93. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, and Nicholson RI. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer. 2004; 11: 793-814. doi: 10.1677/erc.1.00799.

94. Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Giustini L, Silva R, Zaniboni A, Biscotti T, Biagetti S, Galizia E, Loupakis F, Falcone A, Bariarzi I, et al. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. Ann Oncol. 2012; 23: 1706-12. doi: 10.1093/annonc/mdr558.

95. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O’Connor M, Yao Y, Pirratt C, Buck E, Eyzyguirre A, Arnold LD, Gibson NW, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther. 2007; 6: 2158-67. doi: 10.1158/1535-7163.MCT-07-0070.

96. Reids DL, Vakiani E, Fakih MG, Saffi MW, Hecht JR, Goodman-Davis N, Hollywood E, Shia J, Schwartz J, Chandrawansa K, Dontabhaktuni A, Youssoufian H, Solt DB, et al. Randomized, phase II study of the insulin-like growth factor-I receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol. 2010; 28: 4240-6. doi: 10.1200/JCO.2010.30.4154.

97. Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, et al. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximb.
and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. J Natl Cancer Inst. 2015; 107: djv258. doi: 10.1093/jnci/djv258.

98. Gherardi E, Birchmeier W, Birchmeier C, and Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12: 89-103. doi: 10.1038/nrc3205.

99. Engelja MA, Zejnullahlu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316: 1039-43. doi: 10.1126/science.1141478.

100. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, et al. MET amplification leads to gefitinib resistance in lung adenocarcinoma with epidermal growth factor receptor activating mutations. Cancer Res. 2008; 68: 9479-87. doi: 10.1158/0008-5472.CAN-08-1643.

101. Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D’Aito E, Berrino L, et al. Increased TGF-alpha as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res. 2013; 19: 6751-65. doi: 10.1158/1078-0432.CCR-13-0423.

102. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, and Weiser MR. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res. 2011; 17: 472-82. doi: 10.1158/1078-0432.CCR-10-0568.

103. Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH, and Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer. 2011; 47: 1231-43. doi: 10.1016/j.ejca.2010.12.019.

104. Yonesaka K, Zejnullahu K, Okamoto I, Sato H, Cappuzzo F, Souglakos J, Erkan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011; 3: 99ra86. doi: 10.1126/scitranslmed.3002442.

105. Bertotti A, Migliardi G, Galimi F, Sassì F, Torti D, Isella C, Cora D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011; 1: 508-23. doi: 10.1158/2159-8290.CD-11-0109.

106. Ciardiello F, and Normanno N. HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. Cancer Discov. 2011; 1: 472-4. doi: 10.1158/2159-8290.CD-11-0261.

107. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352: 786-92. doi: 10.1056/NEJMoa044238.

108. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, and Riely GJ. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19: 2240-7. doi: 10.1158/1078-0432.CCR-12-2246.

109. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet C, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri S, Serrano S, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012; 18: 221-3. doi: 10.1038/nm.2609.

110. Esposito C, Rachiglio AM, La Porta ML, Sacco A, Roma C, Iannaccone A, Tatangelo F, Forgione L, Pasquale R, Barbaro A, Botti G, Ciardiello F, and Normanno N. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol Ther. 2013; 14: 1143-6. doi: 10.4161/cbt.26340.

111. Ellis LM, and Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8: 579-91. doi: 10.1038/nrc2403.

112. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005; 438: 820-7. doi: 10.1038/ nature04186.

113. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, and Tortora G. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res. 2004; 10: 784-93. doi: 10.1158/1078-0432.CCR-1100-03.

114. Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Albanese A, Ciardiello F, and Normanno N. HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011; 1: 508-23. doi: 10.1158/2159-8290.CD-11-0109.

115. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sennige HA, Richel DJ, Voest EE, Dijkstra JR, et al.
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009; 360: 563-72. doi: 10.1056/NEJMoa0808268.

116. Hecht JR, Mitchell E, Chidiae T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, and Amado RG. A randomized phase IIIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009; 27: 672-80. doi: 10.1200/JCO.2008.19.8135.

117. Derangere V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rebe C, and Ghiringhelli F. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget. 2016; 7: 9309-21. doi: 10.18632/oncotarget.7008.

118. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, and Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26: 5705-12. doi: 10.1200/JCO.2008.18.0786.

119. Zhang YJ, Tian XQ, Sun DF, Zhao SL, Xiong H, and Fang JY. Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. Cancer Invest. 2009; 27: 273-85. doi: 10.1080/07357900802314893.

120. Markman B, Atzori F, Perez-Garcia J, Tabernero J, and Baselga J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol. 2010; 21: 683-91. doi: 10.1093/annonc/mdp347.

121. Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, Taylor M, Wood H, Hutchins G, Foster JM, Oumie A, Spink KG, Brown SR, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016; 238: 562-70. doi: 10.1002/path.4679.

122. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006; 439: 358-62. doi: 10.1038/nature04304.

123. Queralt B, Cuyas E, Bosch-Barrera J, Massaguera A, de Llorens R, Martin-Castillo B, Brunet J, Salazar R, and Menendez JA. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Oncotarget. 2016; 7: 82185-82199. doi: 10.18632/oncotarget.11985.